NRX Pharmaceuticals, Inc. (NRXP): Nasdaq/NYSE listing notice — Nasdaq grants NRx Pharma transfer to Capital Market; compliance due April 16, 2024

NRX Pharmaceuticals, Inc.

Nasdaq Hearings Panel grants transfer to Capital Market; must comply with all criteria by April 16, 2024.
Company believes it has satisfied the $35M market value of listed securities requirement.
Must evidence compliance with $1.00 minimum bid price for ten consecutive business days by April 16.
Aims to file first NDA for NRX-100 (ketamine) for acute suicidal depression this quarter.
Phase 2b/3 trial results for NRX-101 in suicidal bipolar depression expected before compliance date.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

NRX Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5550(a)(2)

Exact text from the filing

October 17, 2023, NRx Pharmaceuticals, Inc. (the “Company”) received formal notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s non-compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Rule”), the Company’s securities were subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company timely requested a hearing before the Panel, which hearing

View on SEC.gov

Browse all listing & compliance notices →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-005888

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.